Akebia Therapeutics (AKBA) Research & Development (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Research & Development data on file, last reported at $14.8 million in Q1 2026.

• On a quarterly basis, Research & Development rose 51.8% year-over-year to $14.8 million in Q1 2026; TTM through Mar 2026 was $41.8 million, a 10.86% increase from a year earlier, with the FY2025 full-year figure at $62.4 million, up 65.62% from the prior year.
• Research & Development for Q1 2026 stood at $14.8 million, up from $1.0 million in the prior quarter.
• Over the last five years, Research & Development for AKBA reached as high as $43.8 million in Q1 2022 and fell as low as $1.0 million in Q4 2025.
• Historically, Research & Development has averaged $16.6 million across 5 years, with a median of $13.3 million in 2023.
• On a YoY basis, Research & Development climbed as much as 76.08% in 2025 and fell as far as 91.52% in 2025.
• Year by year, Research & Development stood at $32.1 million in 2022, then slumped by 69.27% to $9.9 million in 2023, then climbed by 19.47% to $11.8 million in 2024, then slumped by 91.52% to $1.0 million in 2025, then soared by 1380.7% to $14.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.8 million in Q1 2026, $1.0 million in Q4 2025, and $14.9 million in Q3 2025.